Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Hyperphosphatemia Drugs Market by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), By Application (Hospitals, Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Hyperphosphatemia Drugs Market by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), By Application (Hospitals, Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 195845 3300 Pharma & Healthcare 377 230 Pages 4.7 (48)
                                          

The global hyperphosphatemia drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic kidney disease and other conditions that lead to hyperphosphatemia, such as cancer and diabetes. The increase in the number of patients with chronic kidney disease will drive the demand for phosphate binders in hospitals and clinics. Aluminum Phosphate Binder: Aluminum phosphate binders are used for treating hyperphosphatemia by binding phosphorus in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. This type of binder is available as aluminum hydroxide or aluminum carbonate gel capsules or tablets, which are taken orally with water before meals or after meals. Aluminum phosphate binders are used for treating hyperphosphatemia by binding phosphorus in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. Iron Phosphate Binder: Iron phosphate binders are used for treating hyperphosphatemia by binding phosphorus in blood plasma and tissues through an iron-containing complex called ferric pyrophosphate (FPP). These types of binders can be administered intravenously (IV) through a needle inserted into a vein; intramuscularly (IM) through a needle inserted into muscle; subcutaneously (SC) under skin; intraperitoneally (IP) inside abdomen; rectally via suppository; vaginally via vaginal insert tablet/suppository/gel capsule/tablet/capsule; transdermally via patch applied on skin surface near stomach area; nasogastric tube inserted through nose down throat passage towards stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician); oral route either as liquid suspension mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc; topical route either as cream applied on skin surface near stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician); oral route either as liquid suspension mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc; topical route either as cream applied on skin surface near stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician). Magnesium Phosphate Binder: Magnesium phosphate binds phosphates within cells and prevents their release back into circulation when they would otherwise be excreted out in urine due to renal failure caused due to various reasons including diabetes mellitus type 2, chronic kidney disease stage 3-5 CKD), congestive heart failure CHF), hypertension HTN), nephrotic syndrome NS), polycystic kidney PKD), primary renal tubular acidosis PRTA). It also helps maintain normal levels of magnesium within cells while reducing serum levels below normal range so that they do not interfere adversely affect cardiac function erythrocyte production erythropoiesis erythropoiesis).

Some Of The Growth Factors Of This Market:

  1. The increasing prevalence of chronic kidney disease and the associated hyperphosphatemia is a major factor driving the growth of the market.
  2. The increasing number of patients with end-stage renal disease is also a major factor driving the growth of this market.
  3. The increase in awareness about hyperphosphatemia and its treatment options among physicians is also a major factor driving this market's growth.
  4. Increasing incidence rates for chronic kidney disease, which leads to an increased prevalence of hyperphosphatemia, are also factors that are expected to drive this market's growth over the forecast period (2017-2026).
  5. Increasing geriatric population base in developed countries such as North America and Europe is another key driver for this market's growth over the forecast period (2017-2026).

Industry Growth Insights published a new data on “Hyperphosphatemia Drugs Market”. The research report is titled “Hyperphosphatemia Drugs Market research by Types (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), By Applications (Hospitals, Clinics, Others), By Players/Companies Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Hyperphosphatemia Drugs Market Research Report

By Type

Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder

By Application

Hospitals, Clinics, Others

By Companies

Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

230

Number of Tables & Figures

161

Customization Available

Yes, the report can be customized as per your need.


Global Hyperphosphatemia Drugs Industry Outlook


Global Hyperphosphatemia Drugs Market Report Segments:

The global Hyperphosphatemia Drugs market is segmented on the basis of:

Types

Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals, Clinics, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Keryx Biopharmaceuticals
  2. Sanofi
  3. Shire
  4. Vifor Pharma
  5. Amgen
  6. Bayer

Global Hyperphosphatemia Drugs Market Overview


Highlights of The Hyperphosphatemia Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Aluminum Phosphate Binder
    2. Iron Phosphate Binder
    3. Magnesium Phosphate Binder
    4. Calcium Phosphate Binder
  1. By Application:

    1. Hospitals
    2. Clinics
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Hyperphosphatemia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Hyperphosphatemia Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Hyperphosphatemia drugs are medications that help to lower blood phosphate levels. This can help to prevent or treat a variety of health problems, including kidney stones and heart disease.

Some of the key players operating in the hyperphosphatemia drugs market are Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer.

The hyperphosphatemia drugs market is expected to register a CAGR of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Hyperphosphatemia Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Hyperphosphatemia Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Hyperphosphatemia Drugs Market - Supply Chain
   4.5. Global Hyperphosphatemia Drugs Market Forecast
      4.5.1. Hyperphosphatemia Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Hyperphosphatemia Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Hyperphosphatemia Drugs Market Absolute $ Opportunity

5. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      5.3.1. Aluminum Phosphate Binder
      5.3.2. Iron Phosphate Binder
      5.3.3. Magnesium Phosphate Binder
      5.3.4. Calcium Phosphate Binder
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      6.3.1. Hospitals
      6.3.2. Clinics
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026

9. North America Hyperphosphatemia Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      9.4.1. Hospitals
      9.4.2. Clinics
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      9.7.1. Aluminum Phosphate Binder
      9.7.2. Iron Phosphate Binder
      9.7.3. Magnesium Phosphate Binder
      9.7.4. Calcium Phosphate Binder
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026

10. Latin America Hyperphosphatemia Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      10.4.1. Hospitals
      10.4.2. Clinics
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      10.7.1. Aluminum Phosphate Binder
      10.7.2. Iron Phosphate Binder
      10.7.3. Magnesium Phosphate Binder
      10.7.4. Calcium Phosphate Binder
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026

11. Europe Hyperphosphatemia Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      11.4.1. Hospitals
      11.4.2. Clinics
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      11.7.1. Aluminum Phosphate Binder
      11.7.2. Iron Phosphate Binder
      11.7.3. Magnesium Phosphate Binder
      11.7.4. Calciu Phosphate Binder
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Hyperphosphatemia Drugs Demand Share, 2019-2026

12. Asia Pacific Hyperphosphatemia Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      12.4.1. Hospitals
      12.4.2. Clinics
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      12.7.1. Aluminum Phosphate Binder
      12.7.2. Iron Phosphate Binder
      12.7.3. Magnesium Phosphate Binder
      12.7.4. Calcium Phosphate Binder
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Hyperphosphatemia Drugs Demand Share, 2019-2026

13. Middle East & Africa Hyperphosphatemia Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
      13.4.1. Hospitals
      13.4.2. Clinics
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
      13.7.1. Aluminum Phosphate Binder
      13.7.2. Iron Phosphate Binder
      13.7.3. Magnesium Phosphate Binder
      13.7.4. Calcium Phosphate Binder
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Hyperphosphatemia Drugs Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Hyperphosphatemia Drugs Market: Market Share Analysis
   14.2. Hyperphosphatemia Drugs Distributors and Customers
   14.3. Hyperphosphatemia Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Keryx Biopharmaceuticals
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Sanofi
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Shire
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Vifor Pharma
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Amgen
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Bayer
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. COMPANY7
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. COMPANY8
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us